Home › Medicines › Cefokid DS
বাংলায় দেখুন
💊

Cefokid DS

Powder for Suspension

🧬 Cefpodoxime Proxetil 🏢 Euro Pharma Ltd.
Generic Name Cefpodoxime Proxetil
Manufacturer Euro Pharma Ltd.
Unit Price 50 ml bottle: ৳ 175.00

🔹 Indications

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Pharmacology

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Dosage & Administration

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Interaction

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Contraindications

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Side Effects

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Pregnancy & Lactation

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

🔹 Precautions & Warnings

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below:
  • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
  • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
  • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
  • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
  • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
  • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
  • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).

💡 Frequently Asked Questions

Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below: Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-la...
Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below: Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-la...
Cefokid DS is indicated for the treatment of infections caused by susceptible microorganism, listed below: Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-la...

User Reviews

⭐
No reviews yet!
Be the first to share your experience.

Write a Review

Alternative Medicines
(Same Generic)

Cefdox Powder for Suspension

ACI Limited

50 ml bottle: ৳ 98.67

Cefipod Powder for Suspension

Asiatic Laboratories Ltd.

50 ml bottle: ৳ 98.00

Cefipod Pediatric Drops

Asiatic Laboratories Ltd.

15 ml bottle: ৳ 60.00

Cefobid Powder for Suspension

UniMed UniHealth Pharmaceuticals Ltd.

50 ml bottle: ৳ 98.00

Cefodox Powder for Suspension

Bristol Pharmaceuticals Ltd.

50 ml bottle: ৳ 95.00

Cefodox Capsule

Bristol Pharmaceuticals Ltd.

Unit Price: ৳ 22.00 (4's pack: ৳ 88.00)

Cefomin Powder for Suspension

Popular Pharmaceuticals Ltd.

50 ml bottle: ৳ 90.00

Ceforan Powder for Suspension

Drug International Ltd.

50 ml bottle: ৳ 85.00

Ceforan DS Powder for Suspension

Drug International Ltd.

50 ml bottle: ৳ 175.00

Cepoxid Powder for Suspension

Apex Pharma Ltd.

50 ml bottle: ৳ 100.00